Chilton Capital Management LLC Acquires 235,131 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Chilton Capital Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 125,738.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 235,318 shares of the biopharmaceutical company's stock after acquiring an additional 235,131 shares during the period. Chilton Capital Management LLC's holdings in Gilead Sciences were worth $26,367,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the 1st quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter worth $29,000. Core Alternative Capital increased its position in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the period. Annis Gardner Whiting Capital Advisors LLC increased its position in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the period. Finally, Investment Research & Advisory Group Inc. increased its position in Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Cantor Fitzgerald began coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Down 0.2%

Shares of GILD traded down $0.24 during trading hours on Friday, reaching $111.28. 4,039,811 shares of the stock traded hands, compared to its average volume of 7,706,267. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a fifty day simple moving average of $107.02 and a 200 day simple moving average of $104.02. Gilead Sciences, Inc. has a 52 week low of $66.34 and a 52 week high of $119.96. The company has a market cap of $138.42 billion, a price-to-earnings ratio of 23.43, a PEG ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.32) EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is 66.53%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares in the company, valued at approximately $13,238,908.56. The trade was a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,500 shares of company stock valued at $6,340,745. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.